Send to

Choose Destination
Cell Death Differ. 2019 Jul;26(7):1267-1282. doi: 10.1038/s41418-018-0205-5. Epub 2018 Sep 25.

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma.

Author information

IRCCS, Regina Elena National Cancer Institute, Rome, Italy.
Department of Experimental and Clinical Medicine, University "Magna Graecia" of Catanzaro, Catanzaro, Italy.
Department of Molecular and Clinical Medicine, University of Roma "Sapienza", Rome, Italy.
IRCCS, National Cancer Institute of Naples "Fondazione G. Pascale", Naples, Italy.
Division of Pulmonary Disease and Critical Care Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
IRCCS, Regina Elena National Cancer Institute, Rome, Italy.


Drug resistance imposes severe limitations to the efficacy of targeted therapy in BRAF-mutated metastatic melanoma. Although this issue has been mitigated by the development of combination therapies with BRAF plus MEK inhibitors, drug resistance inevitably occurs with time and results in clinical recurrences and untreatable disease. Hence, there is strong need of developing new combination therapies and non-invasive diagnostics for the early identification of drug-resistant patients. We report here that the development of drug resistance to BRAFi is dominated by a dynamic deregulation of a large population of miRNAs, leading to the alteration of cell intrinsic proliferation and survival pathways, as well as of proinflammatory and proangiogenic cues, where a prominent role is played by the miR-199b-5p/VEGF axis. Significant alterations of miRNA expression levels are detectable in tumor biopsies and plasma from patients after disease recurrence. Targeting these alterations blunts the development of drug resistance.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center